1 Result: Longeveron
Longeveron's Lomecel-B shows promise for HLHS patients; Plug Power and Genius Sports report mixed Q1 earnings
May 09th, 2023
Longeveron Inc. (Nasdaq: LGVN) released new long-term follow-up data from its ELPIS I trial, highlighting the potential survival benefit of Lomecel-B for patients with hypoplastic left heart syndrome (HLHS). HLHS is a rare and life-threatening congen. Read more
Load More Content
Member Login